Juliana Folloni Fernandes

List of Publications by Year
in descending order

42	1,143	687363 13	414414 32
papers	citations	h-index	g-index

43	43	43	1960
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet, The, 2014, 383, 436-448.	13.7	322
2	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. Journal of Allergy and Clinical Immunology, 2018, 141, 1036-1049.e5.	2.9	233
3	Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood?. Blood, 2012, 119, 2949-2955.	1.4	106
4	Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood, 2020, 136, 1201-1211.	1.4	97
5	Outcome of SARS-CoV-2 Infection in 121 Patients with Inborn Errors of Immunity: A Cross-Sectional Study. Journal of Clinical Immunology, 2021, 41, 1479-1489.	3.8	56
6	Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. Haematologica, 2014, 99, 1509-1515.	3.5	48
7	Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation. British Journal of Haematology, 2007, 137, 248-251.	2.5	41
8	Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases. Biology of Blood and Marrow Transplantation, 2020, 26, 1923-1929.	2.0	34
9	Autoimmune manifestations in SCID due to IL7R mutations: Omenn syndrome and cytopenias. Human Immunology, 2014, 75, 662-666.	2.4	27
10	Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2020, 26, 2311-2317.	2.0	26
11	COVID-19 after hematopoietic stem cell transplantation: report of two children. Bone Marrow Transplantation, 2021, 56, 713-715.	2.4	22
12	Identification of a novel fusion TBL1XR1â€“PDGFRB in a patient with acute myeloid leukemia harboring the DEKâ€“NUP214 fusion and clinical response to dasatinib. Leukemia and Lymphoma, 2017, 58, 2969-2972.	1.3	17
13	Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation. Bone Marrow Transplantation, 2018, 53, 392-399.	2.4	16
14	COVID-19 in HSCT recipients: a collaborative study of the Brazilian Society of Marrow Transplantation (SBTMO). Bone Marrow Transplantation, 2022, 57, 453-459.	2.4	14
15	Transplantation of Hematopoietic Stem Cells for Primary Immunodeficiencies in Brazil: Challenges in Treating Rare Diseases in Developing Countries. Journal of Clinical Immunology, 2018, 38, 917-926.	3.8	13
16	Latin American consensus on the supportive management of patients with severe combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2019, 144, 897-905.	2.9	11
17	Lomentospora prolificans fungemia in hematopoietic stem cell transplant patients: First report in South America and literature review. Transplant Infectious Disease, 2018, 20, e12908.	1.7	9
18	Development of BK Virus-Associated Hemorrhagic Cystitis (HC) Is Associated with Decreased Survival Post-Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). Blood, 2012, 120, 1933-1933.	1.4	8

#	Article	IF	Citations
19	Targetedâ€dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 ÂµMolâ‚±min. A historically controlled clinical trial. Hematological Oncology, 2020, 38, 773-781.	1.7	6
20	Clinical Characteristics and Outcomes of COVID-19 in HSCT Recipients. Blood, 2020, 136, 19-19.	1.4	5
21	Simultaneous Occurrence of Biphenotypic T Cell/Myeloid Lesions Involving t(12;13)(p13;q14) in a Pediatric Patient. Acta Haematologica, 2012, 127, 165-169.	1.4	4
22	Pharmacokinetics analysis results are similar for oral compared to intravenous busulfan in patients undergoing hematopoietic stem cell transplantation, except for the earlier onset of mucositis. A controlled clinical study. Bone Marrow Transplantation, 2019, 54, 1799-1804.	2.4	4
23	Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Acute Myeloid Leukemia in Brazil: A Multicentric Retrospective Study. Cell Transplantation, 2020, 29, 096368972094917.	2.5	4
24	Allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiencies: Hospital Israelita Albert Einstein experience. Einstein (Sao Paulo, Brazil), 2011, 9, 140-144.	0.7	3
25	Eosinophil chimerism in the differential diagnosis between DEK-NUP214-positive acute myeloid leukaemia relapse and chronic graft-versus-host disease. Journal of Clinical Pathology, 2015, 68, 950-952.	2.0	3
26	Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil. Pediatric Transplantation, 2020, 24, e13789.	1.0	3
27	Radiological patterns of pulmonary fungal infection in pediatric hematology and oncology patients. Radiologia Brasileira, 2022, 55, 78-83.	0.7	3
28	Weight Gain in the First 10 Days after Hematopoietic Stem Cell Transplantation (HSCT) Is a Risk Factor for Early Mortality. Blood, 2014, 124, 2471-2471.	1.4	2
29	Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2). Blood, 2020, 136, 8-9.	1.4	2
30	Haploidentical nonâ€myeloablative stem cell transplantation as Salvage for graft failure in a patient with juvenile myelomonocytic leukemia. Pediatric Blood and Cancer, 2011, 57, 1084-1084.	1.5	1
31	Cytomegalovirus Infection and Lymphopenia Are Associated with Increased Mortality Post Autologous Stem Cell Transplantation. Blood, 2012, 120, 4208-4208.	1.4	1
32	Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: children and adolescents. Einstein (Sao Paulo, Brazil), 2021, 19, eAE5254.	0.7	1
33	Population Pharmacokinetic Study of a Test Dose Busulfan Patients Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, S265.	2.0	0
34	Impact of Time to Lymphocyte Recovery on Survival Post Autologous Stem Cell Transplantation.. Blood, 2010, 116, 4540-4540.	1.4	0
35	Allogeneic Stem Cell Transplantation for Sickle Cell Disease in Brazil: The Time Is Now!. Blood, 2011, 118, 1064-1064.	1.4	0
36	Prediction of Apheresis Peripheral Blood Stem Cell Yield Based on Pre Apheresis Absolute Peripheral Blood Stem Cell Counts,. Blood, 2011, 118, 4047-4047.	1.4	0

#	Article	IF	Citations
37	Eosinophil Chimerism In The Differential Diagnosis Between DEK-CAN+ Acute Myeloid Leukemia Relapse and Chronic Graft Versus Host Disease. Blood, 2013, 122, 5004-5004.	1.4	0
38	Fluid Accumulation During The Early Phases Of Hematopoietic Stem Cell Transplantation (HSCT) Is Associated With An Increased Risk Of Mortality and Complications. Blood, 2013, 122, 4572-4572.	1.4	0
39	The Clinical and Therapeutic Drug Monitoring of Oral and Intravenous Busulfan in Patients with Acute Leukemia That Underwent to Stem Cell Transplantation with a Test Dose of Busulfan. Blood, 2014, 124, 5841-5841.	1.4	0
40	High Incidence of Neurological Complications in Patients with Sickle Anemia Disease Undergoing Related Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Early Diagnosis and Treatment Can Chance the Prognosis. Blood, 2014, 124, 5941-5941.	1.4	0
41	Early MMF Discontinuation Is an Effective and Safe Measure to Decrease CMV Reactivation in Patients Submitted to Unmanipulated Haploidentical Transplant with Post-Cy Immunosuppression. Blood, 2016, 128, 2216-2216.	1.4	0
42	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia. Hematology, Transfusion and Cell Therapy, 2021, 43, S13-S21.	0.2	0